万谟彬;王福生;高志良;陈新月;张鸿飞;鲁凤民;韦嘉;郭瑛;

• 1:海军军医大学第一附属医院感染科
• 2:解放军总医院第五医学中心感染病医学部国家感染性疾病临床医学研究中心
• 3:中山大学附属第三医院感染性疾病科
• 4:首都医科大学附属北京佑安医院肝病中心一科

摘要(Abstract)：

干扰素α用于慢性乙型肝炎抗病毒治疗在临床实践中积累了丰富的经验,最初的治疗目标是维持患者病毒学持续应答,以改善长期预后。更深入的临床实践和研究提示,聚乙二醇干扰素α治疗慢性乙型肝炎在部分患者中可能实现临床治愈,从而引起极大关注。临床治愈可以作为某些优势人群的治疗目标已逐渐形成共识,但如何通过调整聚乙二醇干扰素α的治疗方法来进一步提高临床治愈率仍缺乏大样本、设计良好、有对照的临床试验数据的支持。关于以临床治愈为目标的初治患者的适合疗程、一次性治疗还是分阶段治疗、持续性治疗还是间歇性治疗,以及停药指征和复发相关因素等诸多治疗策略问题尚需要更深入地研究。近年来,由研究者发起的以临床治愈为首要治疗目标的研究逐渐增多,奠定了良好的基础。本文旨在强调要加强和重视以临床治愈为治疗终点的聚乙二醇干扰素α治疗策略的研究,以进一步提高临床治愈率。

关键词(KeyWords)： 慢性乙型肝炎;临床治愈;聚乙二醇干扰素α;治疗策略;间歇性治疗

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(82170612);; “十三五”国家科技重大专项(2018ZX10302204)

作者(Authors): 万谟彬;王福生;高志良;陈新月;张鸿飞;鲁凤民;韦嘉;郭瑛;

参考文献(References)：

• [1]中华医学会感染病学分会，中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版)[J].临床肝胆病杂志，2019，35(12)：2648-2669.
• [2]European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J].J Hepatol,2017,67(2):370-398.
• [3]TERRAULT N A,LOK A S F,MCMAHON B J,et al.Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J].Hepatology,2018,67(4):1560-1599.
• [4]MARCELLIN P,HEATHCOTE E J,BUTI M,et al.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J].N Engl J Med,2008,359(23):2442-2455.
• [5]HU C,SONG Y,TANG C,et al.Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen-positive Chronic Hepatitis B:A Real-world Experience[J].Clin Ther,2021,43(3):572-581.
• [6]CAO Z,LIU Y,MA L,et al.A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha[J].Hepatology,2017,66(4):1058-1066.
• [7]LI M,ZHANG L,LU Y,et al.Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a[J].Virol Sin,2021,36(2):311-320.
• [8]HU P,SHANG J,ZHANG W,et al.HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog:New Switch Study[J].J Clin Transl Hepatol,2018,6(1):25-34.
• [9]MICCO L,PEPPA D,LOGGI E,et al.Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B[J].J Hepatol,2013,58(2):225-233.
• [10]THIMME R,DANDRI M.Dissecting the divergent effects of interferon-alpha on immune cells:time to rethink combination therapy in chronic hepatitis B?[J].J Hepatol,2013,58(2):205-209.
• [11]ALAWAD A S,AUH S,SUAREZ D,et al.Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen[J].Clin Gastroenterol Hepatol,2020,18(3):700-709.
• [12]LOK A S,ZOULIM F,DUSHEIKO G,et al.Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B[J].Hepatol Commun,2019,4(1):8-20.
• [13]WU Y,LIU Y,LU J,et al.Durability of Interferon-induced Hepatitis B Surface Antigen Seroclearance[J].Clin Gastroenterol Hepatol,2020,18(2):514-516.
• [14]LI M H,YI W,ZHANG L,et al.Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy[J].J Viral Hepat,2019,26 Suppl 1:32-41.
• [15]BAZINET M,P?NTEA V,PLACINTA G,et al.Safety and Efficacy of 48 Weeks REP 2139 or REP 2165,Tenofovir Disoproxil,and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Na?ve to Nucleos(t)ide Therapy[J].Gastroenterology,2020,158(8):2180-2194.
• [16]YUAN M F,LIM Y S,CLOUTIER D,et al.Preliminary on-treatment data from a phase 2 study evaluating VIR-2218 in combination with pegylated interferon alfa-2a in participants with chronic hepatitis B infection[J].J Hepatol,2021,75(2):PO-824.
• [17]SCALFARO P,HEO J,LIU C,et al.A phase 2 study testing FXR agonist Vonafexor in treatment naive patients with chronic hepatitis B (CHB):preliminary week 16 results[J].J Hepatol,2021,75(2):PO-2844.